Expanding Global Access: Two New Market Authorizations for Venus Remedies
From pain relief to cancer care, Venus Remedies is expanding access to trusted treatments with new approvals in Niger and Ethiopia.
Venus Remedies continues to expand its global presence with a commitment to accessible and quality healthcare.
We have taken another meaningful step in our journey with the approval of two key products in emerging markets. Paracetamol 1000 mg has received authorization in Niger, marking the company’s first-ever product registration in the country. On the other hand, Concentrated Docetaxel 80 mg/2 ml has been approved in Ethiopia.
Bridging Gaps in Essential Care
These approvals are more than a market entry. They are a bridge that strengthens our access to essential medicine worldwide.
The first time registration of Paracetamol 1000 mg in Niger means that more patients in the region will now have access to trusted, effective treatments. The analgesic drug plays a critical role in managing everyday healthcare and pain management needs. In fact, it is one of the most widely relied upon medicines in clinical care. With this milestone, Venus has ensured that effective medicines are available where they are needed most.
The approval of Docetaxel in Ethiopia addresses a far more specialized need. As a chemotherapy agent used to treat various cancers, it reinforces our oncology expertise and trusted treatment options. Expanding Docetaxel’s availability supports healthcare providers in delivering timely and effective cancer treatment, helping us to extend meaningful care.
Emphasizing the same Ms, Aditi K. Chaudhary, President International Business, Venus Remedies said that, "Expanding our presence across regions is guided by a clear commitment to access and quality. With our entry into Niger and Ethiopia, we continue to bring safe and effective therapies closer to patients. Our focus remains on responsible growth and long-term impact."
Strengthening Global Access
Both of these approvals make our belief stronger in creating high-quality, affordable, and reliable treatments. Our mission to serve critical patients worldwide is only getting stronger with each authorization. The balance between expansion and responsibility continues to define our approach.
The emerging markets build our foundation of excellence in healthcare needs. Adhering to global quality standards, Venus continues to create long-term value in the pharma landscape. The approvals in Niger and Ethiopia are another step in that direction.
